Abstract
The thorny topic of fluoroquinolone use in so-called trivial infections was reviewed in respect of risks and benefits on Nov 4, 2015, when a joint meeting of two US Food and Drug Administration (FDA) advisory committees (antimicrobial drugs and drug safety) was convened to discuss the relative risks and benefits in three infections: acute bacterial sinusitis, acute bacterial exacerbations of chronic bronchitis, and uncomplicated urinary tract infections. 1 US Food and Drug AdministrationJoint Meeting of the Antimicrobial Drugs Advisory Committee Meeting (AMDAC) and the Drug Safety and Risk Management Advisory Committee (DSaRM). http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/anti-infectivedrugsadvisorycommittee/ucm470444.pdfDate: 2015 Google Scholar
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
